NASDAQ : RYTM
Rhythm Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.37B |
| Enterprise Value | 6.15B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 68.85M |
| Shares Outstanding | 68.85M |
| Shares Change (YoY) | +8.09% |
| Shares Change (QoQ) | +0.91% |
| Owned by Insiders (%) | 0.79% |
| Owned by Institutions (%) | 96.52% |
| Float | 56.04M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.57 |
| Forward PS | 15.38 |
| PB Ratio | 61.86 |
| P/TBV Ratio | 64.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 25.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.45 |
| Quick Ratio | 3.00 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.86 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -117.04% |
| Return on Assets (ROA) | -30.96% |
| Return on Invested Capital (ROIC) | -43.64% |
| Return on Capital Employed (ROCE) | -63.96% |
| Weighted Average Cost of Capital (WACC) | 15.26% |
| Revenue Per Employee | $579,512 |
| Profits Per Employee | -$507,783 |
| Employee Count | 414 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.07 |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.07M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -18.72% |
| 50-Day Moving Average | 97.18 |
| 200-Day Moving Average | 97.09 |
| Relative Strength Index (RSI) | 50.25 |
| Average Volume (20 Days) | 668,994 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.00M |
| Short Previous Month | 10.77M |
| Short % of Shares Out | 15.98% |
| Short % of Float | 19.64% |
| Short Ratio (days to cover) | 13.64 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 239.92M |
| Gross Profit | 213.53M |
| Operating Income | -200.63M |
| Pretax Income | -204.28M |
| Net Income | -210.22M |
| EBITDA | -199.55M |
| EBIT | -200.63M |
| Loss Per Share | -$3.12 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 330.90M |
| Total Debt | 109.78M |
| Net Cash | 221.11M |
| Net Cash Per Share | $3.21 |
| Equity (Book Value) | 217.30M |
| Book Value Per Share | 1.50 |
| Working Capital | 302.98M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -105.35M |
| Capital Expenditures | -953,000 |
| Depreciation & Amortization | 1.08M |
| Net Borrowing | n/a |
| Free Cash Flow | -106.30M |
| FCF Per Share | -$1.54 |
Margins
| Measure | Value |
|---|
| Gross Margin | 89.00% |
| Operating Margin | -83.62% |
| Pretax Margin | -85.14% |
| Profit Margin | -85.59% |
| EBITDA Margin | -83.17% |
| EBIT Margin | -83.62% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.09% |
| Shareholder Yield | -8.09% |
| Earnings Yield | -3.37% |
| FCF Yield | -1.67% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $140.53 |
| Price Target Difference | 51.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 68.35% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |